The Fuchs Endothelial Corneal Dystrophy market is anticipated to increase due to a rising number of diagnostic tests, use of various medications for the treatment such as nasal sprays, nasal corticosteroids, and decongestants in the 7MM region.
DelveInsight’s Fuchs Endothelial Corneal Dystrophy Market Insights report proffers a detailed comprehension of the Fuchs Endothelial Corneal Dystrophy market size by treatment, epidemiology, emerging therapies, Fuchs Endothelial Corneal Dystrophy market share of the individual therapies, current and forecasted Fuchs Endothelial Corneal Dystrophy market size from 2019 to 2032 segmented into 7MM [the US, EU5 (the UK, Italy, Spain, France, and Germany), and Japan].
Some of the salient features from the Fuchs Endothelial Corneal Dystrophy Market Report:
- As per DelveInsight’s analysis, the Fuchs Endothelial Corneal Dystrophy market in the 7MM is expected to grow at a considerable CAGR during the study period 2019-2032.
- The total number of prevalent cases of Fuchs Endothelial Corneal Dystrophy associated in 7MM countries was 17 million in 2020
- Key Fuchs Endothelial Corneal Dystrophy companies such as Kowa Pharmaceuticals, Trefoil Therapeutics, ProQR Therapeutics, Emmecell, and others are currently developing Fuchs Endothelial Corneal Dystrophy treatment therapies.
- The Fuchs Endothelial Corneal Dystrophy pipeline therapies, including Ripasudil Hydrochloride Hydrate, TTHX1114, and others, are expected to launch in the study period 2019–2032.
- Overall, the launch of novel drugs, during the forecasted period, along with improved diagnosis, would fuel the Fuchs Endothelial Corneal Dystrophy market during the forecasted period (2022–2032).
For further information on Market Impact by Therapies, Download the Fuchs Endothelial Corneal Dystrophy Market sample @ Fuchs Endothelial Corneal Dystrophy Therapeutics Market Landscape
Fuchs Endothelial Corneal Dystrophy Overview
Endothelial cells in the cornea of the eye degenerate or get damaged in Fuchs Endothelial Corneal Dystrophy (FECD), also known as Fuchs’ endothelial dystrophy. It can either be sporadic or autosomal dominantly inherited. The thickening of the cornea, which causes glare, a halo, and decreased visual acuity, is a hallmark of Fuchs’ dystrophy. It may occasionally result in corneal blindness. Elderly people with FECD are more likely to have an asymmetrical, bilateral, slowly progressing edoema of the cornea than younger patients. During an eye exam, guttae deposits are typically visible. They often start in the cornea’s center and eventually expand outward.
The continual cell death within the cornea caused by these guttae contributes to the deteriorating eyesight issues. On the cornea, tiny blisters may form; when they burst, they may cause eye pain.
Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation
The Fuchs Endothelial Corneal Dystrophy Market Report proffers epidemiological analysis for the study period 2019–-2032 in the 7MM segmented into-
- Prevalence of Fuchs Endothelial Corneal Dystrophy
- Type-specific cases of Fuchs Endothelial Corneal Dystrophy
- Gender-specific incidence of Fuchs Endothelial Corneal Dystrophy
Learn more about the Fuchs Endothelial Corneal Dystrophy Population Trends for the 7MM by downloading @ Fuchs Endothelial Corneal Dystrophy Epidemiological Forecast Report
Fuchs Endothelial Corneal Dystrophy Market
By examining the effect of existing therapies on the market, unmet needs, drivers and barriers, and demand for better technology, the Fuchs Endothelial Corneal Dystrophy market outlook report aids in the development of a detailed understanding of the historical, present, and forecasted Fuchs Endothelial Corneal Dystrophy market trends. The Fuchs Endothelial Corneal Dystrophy market report offers an in-depth analysis of the upcoming trends for each marketed drug and early-stage pipeline therapy by assessing their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, growing patient pool, covered patient segment, anticipated launch year, competition with other therapies, brand value, and their impact on the market.
Discover which therapy is expected to grab a substantial Fuchs Endothelial Corneal Dystrophy market share by downloading the report snapshot @ Fuchs Endothelial Corneal Dystrophy Market Landscape
Key Fuchs Endothelial Corneal Dystrophy Pipeline Therapies and Companies
- TTHX1114: Trefoil Therapeutics
- Ripasudil Hydrochloride Hydrate: Kowa Pharmaceuticals
To know about more pipeline therapies covered in the report, @ Fuchs Endothelial Corneal Dystrophy Pipeline Analysis, Clinical Trials, and Emerging Therapies
Fuchs Endothelial Corneal Dystrophy Market Dynamics
There are no pharmaceutical treatments for Fuchs Endothelial Corneal Dystrophy that have received FDA approval . While symptomatic therapies are employed in the early stages, severe instances necessitate surgical intervention. Lamellar endothelial keratoplasty (EK) operations with minimally invasive techniques can be used in cases where the condition is severe. For patients with visually significant Fuchs’ dystrophy, penetrating keratoplasty, or a full-thickness corneal transplant, was the most popular technique. A new set of techniques, such as Descemet’s stripping automated endothelial keratoplasty (DSAEK), Descemet’s membrane endothelial keratoplasty (DMEK), and Descemetorhexis without endothelial keratoplasty, are, however, replacing this one (DWEK).
Patients are advised to use topical steroids for the rest of their life to suppress their immune response and prevent rejection of the transplanted cells because donor cornea may be rejected after the transplant. Commonly prescribed corticosteroid medicine is dexamethasone. Currently, medical procedures are used in conjunction with surgery.
Know which Fuchs Endothelial Corneal Dystrophy therapy is expected to score the touchdown first @ Fuchs Endothelial Corneal Dystrophy Market Landscape and Forecast
Scope of the Fuchs Endothelial Corneal Dystrophy Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Fuchs Endothelial Corneal Dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, ProQR Therapeutics, Emmecell
- Key Fuchs Endothelial Corneal Dystrophy Pipeline Therapies: Ripasudil Hydrochloride Hydrate, TTHX1114
- Therapeutic Assessment: Fuchs Endothelial Corneal Dystrophy current marketed and emerging therapies
- Market Dynamics: Fuchs Endothelial Corneal Dystrophy market drivers and Fuchs Endothelial Corneal Dystrophy market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement
Discover more about the future market share of Fuchs Endothelial Corneal Dystrophy treatment therapies @ Fuchs Endothelial Corneal Dystrophy Market Forecast
Table of Contents
| 1 | Key Insights |
| 2 | Report Introduction of Fuchs Endothelial Corneal Dystrophy |
| 3 | Fuchs Endothelial Corneal Dystrophy: Market overview at a glance |
| 4 | Disease Background and Overview of Fuchs Endothelial Corneal Dystrophy |
| 5 | Fuchs Endothelial Corneal Dystrophy Epidemiology and Patient Population |
| 6 | 7MM Total Prevalent Patient Population of Fuchs Endothelial Corneal Dystrophy |
| 7 | Country Wise-Epidemiology of Fuchs Endothelial Corneal Dystrophy |
| 8 | Executive Summary of Fuchs Endothelial Corneal Dystrophy |
| 9 | Management and Treatment of Fuchs Endothelial Corneal Dystrophy |
| 10 | Fuchs Endothelial Corneal Dystrophy Patient Journey |
| 11 | Fuchs Endothelial Corneal Dystrophy Case Reports |
| 12 | Fuchs Endothelial Corneal Dystrophy Marketed Therapies |
| 13 | Fuchs Endothelial Corneal Dystrophy Emerging Therapies |
| 14 | Fuchs Endothelial Corneal Dystrophy: 7 Major Market Analysis |
| 15 | Fuchs Endothelial Corneal Dystrophy Market Outlook |
| 16 | Unmet Needs in Fuchs Endothelial Corneal Dystrophy |
| 17 | KOL Views |
| 18 | Fuchs Endothelial Corneal Dystrophy Market Drivers |
| 19 | Fuchs Endothelial Corneal Dystrophy Market Barriers |
| 20 | Fuchs Endothelial Corneal Dystrophy SWOT Analysis |
| 21 | Appendix |
| 22 | DelveInsight Capabilities |
| 23 | Disclaimer |
| 24 | About DelveInsight |
For further information on Market Impact by Therapies @ Fuchs Endothelial Corneal Dystrophy Market Analysis
Related Reports
“DelveInsight’s ‘Sinuscope – Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Sinuscope and the historical and forecasted Sinuscope market trends, market drivers, market barriers and major players involved like AMD Global Telemedicine, GAES, Olympus America, asap endoscopic products, XION GmbH, LocaMed, Optim, MedServ, KARL STORZ, Entermed, Henke-Sass, Wolf GmbH, Easmed, Beijing Hamamatsu, Basda, and others.
Paranasal Sinus Cancer Pipeline
DelveInsight’s, “Paranasal Sinus Cancer – Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Paranasal Sinus Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key companies involved such as Exelixis, Bristol-Myers Squibb, Eli Lily, S.L.A. Pharma AG, Celgene, and others.
Airway Management Devices Market
Global Airway Management Devices Market report delivers an in-depth understanding of the Airway Management Devices, historical and forecasted epidemiology as well as key companies involved in pipelines such as Smiths Medical PLC, Narang Medical Limited, Intersurgical Ltd, Teleflex Incorporated, Stryker Corporation, Medtronic PLC, and others.
Asthma Diagnostic Devices Market
“DelveInsight’s ‘Asthma Diagnostic Devices Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Asthma Diagnostic Devices and the historical and forecasted Asthma Diagnostic Devices market trends, drivers, barriers and key companies involved such as Medline Industries, Becton, Dickinson and Company, Siemens Process Instrumentation, Smiths Medical, Vyaire Medical, Nihon Kohden Corporation, Vitalograph, Circassia Limited, Intermedical (UK) Limited, and several others.
DelveInsight’s ‘Pulse Oximeters – Market Insights, Competitive Landscape and Market Forecast – 2027’ report delivers an in-depth understanding of Pulse Oximeters, historical and forecasted Pulse Oximeters market trends, market drivers, market barriers and key companies involved like Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation. Meditech Equipment Co ., Ltd, and several others.
“DelveInsight’s ‘Cough Assist Devices – Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Cough Assist Devices and the historical and forecasted Cough Assist Devices market trends, market drivers & barriers, unmet needs and key companies involved such as Koninklijke Philips N.V, Percussionaire Corp., Emerson, Hill Rom, Dima Italia SRL, and many more.
Interstitial Lung Diseases Pipeline
DelveInsight’s, “Interstitial Lung Diseases – Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key companies involved like AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Blade Therapeutics, Acceleron Pharma and many more.
Artificial Lung Devices Pipeline
DelveInsight’s, “Artificial Lung Devices–Pipeline Insight and Competitive Landscape, 2022,” report provides comprehensive insights about 20+ companies and 23+ pipeline devices in the artificial lung devices pipeline landscape which includes key companies like Lung Biotechnology, Miromatrix, Charles Stark Draper Laboratory Inc, United Therapeutics Corporation, XVIVO Perfusion, Medtronic, Getinge, Xenios AG, ALung Technologies Inc., MC3 Cardiopulmonary, Abiomed and many more.
Interested to know more about the breakthrough happenings? Take a look at the posts below
- Chronic Refractory Cough Market, and the Monopoly of the Over-The-Counter Drugs
- Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Gaurav Bora
+1(919)321-6187